
THIS SUPPLEMENTAL CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this supplemental circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Huakang Biomedical Holdings Company Limited**, you should at once hand this supplemental circular, together with the enclosed revised form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental circular.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
華康生物醫學控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 8622)

**SUPPLEMENTAL CIRCULAR OF THE ANNUAL GENERAL MEETING
IN RELATION TO PROPOSED RE-ELECTION OF RETIRING DIRECTOR
AND
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING**

Capitalised terms used in this cover page shall have the same meanings as those defined in this supplemental circular.

This supplemental circular should be read together with the circular of the annual general meeting (the “**First Circular**”) and the notice of annual general meeting of the Company dated 30 May 2025.

The supplemental notice convening the Annual General Meeting (“**AGM**”) of **Huakang Biomedical Holdings Company Limited** to be held at 1/F, Connaught Harbourfront House, No. 35–36 Connaught Road West, Sheung Wan, Hong Kong on Friday, 27 June 2025 at 4:00 p.m. is set out on pages 8 to 9 of this supplemental circular. A revised form of proxy for use at the AGM is also enclosed. Such revised form of proxy is also published on the Stock Exchange websites (www.hkexnews.hk) and the Company (www.huakangbiomedical.com).

Whether or not you are able to attend the AGM, please complete and sign the enclosed revised form of proxy for use at the AGM in accordance with the instructions printed thereon and return it to the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the AGM (i.e. not later than 4:00 p.m. on Wednesday, 25 June 2025 (Hong Kong time)) or the adjourned meeting (as the case may be). Completion and return of the revised form of proxy will not preclude shareholders from attending and voting in person at the AGM if they so wish.

This supplemental circular will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least 7 days from its date of publication and the Company’s website at www.huakangbiomedical.com.

* *References to time and dates in this supplemental circular are to Hong Kong time and dates.*

Hong Kong, 9 June 2025

CHARACTERISTICS OF GEM

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

CONTENTS

	<i>Page</i>
Definitions	1
 Letter from the Board	
Introduction	3
Proposed Re-election of Retiring Director	4
AGM and Proxy Arrangement	5
Closure of Register of Members	7
Responsibility Statement	7
Recommendation	7
Supplemental Notice of Annual General Meeting	8

DEFINITIONS

In this supplemental circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“AGM”	the annual general meeting of the Company to be held at 1/F, Connaught Harbourfront House, No. 35–36 Connaught Road West, Sheung Wan, Hong Kong on Friday, 27 June 2025 at 4:00 p.m., to consider and, if appropriate, to approve the resolutions contained in the supplemental notice of the meeting which is set out on pages 8 to 9 of this supplemental circular, or any adjournment thereof
“Articles of Association”	the second amended and restated articles of association of the Company currently in force
“Board”	the board of Directors
“Company”	Huakang Biomedical Holdings Company Limited (華康生物醫學控股有限公司), an exempted company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on GEM
“Director(s)”	the director(s) of the Company from time to time
“GEM”	GEM operated by the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM as amended by the Stock Exchange from time to time
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Latest Practicable Date”	5 June 2025, being the latest practicable date prior to the printing of this supplemental circular for ascertaining certain information in this supplemental circular
“SFO”	the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time

DEFINITIONS

“Share(s)”	ordinary share(s) of HK\$0.01 each in the issued capital of the Company or if there has been a subsequent sub-division, consolidation, reclassification or reconstruction of the share capital of the Company, shares forming part of the ordinary equity share capital of the Company
“Shareholder(s)”	holder(s) of Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“%”	per cent

LETTER FROM THE BOARD



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8622)

Executive Directors:

Mr. Zhang Shuguang (*Chairman*)
Mr. Zhang Chunguang
Mr. Poon Lai Yin Michael
Ms. Zhang Yujing

Non-executive Directors:

Dr. Bu Su
Dr. Xu Ming

Independent Non-executive Directors:

Dr. Chow Kwok Fai Joseph
Dr. Cheng Faat Ting Gary
Mr. Tsui Wing Tak

Principal Place of Business in the PRC:

1–3/F and 5/F, Building D, Shenzhen Junxuan
No. 16 Yinkui Road
Kui Xin Community
Kui Chong Office
Dapeng New District, Shenzhen, The PRC

Principal Place of Business in Hong Kong:

Room B, 10/F.
Connaught Harbourfront House
No. 35–36 Connaught Road West, Sheung Wan
Hong Kong

Registered Office:

Cricket Square, Hutchins Drive
P.O. Box 2681, Grand Cayman
KY1-1111, Cayman Islands

Hong Kong, 9 June 2025

To the Shareholders

Dear Sir/Madam,

**SUPPLEMENTAL CIRCULAR OF THE ANNUAL GENERAL MEETING
IN RELATION TO PROPOSED RE-ELECTION OF RETIRING DIRECTOR
AND
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

References are made to the First Circular and the notice of AGM dated 30 May 2025. The purpose of this supplemental circular is to provide you with relevant information, to enable you to make an informed decision on whether to vote for or against, among other matters, the following resolution to be proposed at the AGM.

LETTER FROM THE BOARD

PROPOSED RE-ELECTION OF RETIRING DIRECTOR

Reference is made to the announcement of the Company dated 16 April 2025 in relation to, among other things, the appointment of Ms. Zhang Yujing as an executive Director with effect from 16 April 2025.

Pursuant to Article 83(3), the Directors shall have the power from time to time and at any time to appoint any person as a Director either to fill a casual vacancy on the Board or as an addition to the existing Board. Any Director so appointed shall hold office until the next following annual general meeting of the Company and shall then be eligible for re-election. As such, Ms. Zhang Yujing shall hold office until the AGM and, being eligible, offer herself for re-election at the AGM.

In light of the above, a total of six Directors, namely Mr. Zhang Shuguang, Mr. Zhang Chunguang, Dr. Bu Su, Dr. Xu Ming, Mr. Tsui Wing Tak and Ms. Zhang Yujing will retire and, being eligible, offer themselves for re-election at the AGM. As a result, the resolutions item numbered 2 relating to the re-election of the Directors as set out in the notice of AGM should be deleted in its entirety and replaced by the new resolutions under item numbered 2 as set out in the AGM supplemental notice on pages 8 to 9 of this supplemental circular.

Details of Ms. Zhang Yujing (“**Ms. Zhang**”), which are required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules are set out as follows:

Ms. Zhang, aged 41, was appointed as our executive Director on 16 April 2025. She is responsible for exploring business opportunities and the day-to-day management of our Group.

Ms. Zhang graduated from Hunan Women’s University (湖南女子學院 formerly known as 湖南女子職業大學) in the People’s Republic of China in 2007. Ms. Zhang has extensive experience in healthcare industry.

Ms. Zhang has served as a general manager of Hunan Keyue Biotechnology Co., Ltd. (湖南可悅生物科技有限公司), a company engaged in the research and development and sales of women’s health products. From 2013 to 2023, Ms. Zhang was a general manager of Hua’entang Health Management (Changsha) Company Limited (華恩堂養生管理(長沙)有限公司), a company engaged in providing health and wellness consultation services and research and development of health supplements. Prior to that, she served as a research assistant of the Institute of Molecular Medicine and Therapeutics* (分子藥物與治療研究所) at Central South University (中南大學) in the People’s Republic of China from March 2007 to May 2013.

Ms. Zhang has not held any directorships in any other public companies, the securities of which are or have been listed on any securities market in Hong Kong or overseas in the past three years.

* *English translation is for identification purpose only*

LETTER FROM THE BOARD

Length of service and emoluments

Ms. Zhang has entered into a service contract with the Company for an initial fixed term of three years commencing from the date of appointment and will continue thereafter until terminated by either party giving not less than three months' notice.

Ms. Zhang is also subject to retirement by rotation and eligible for re-election at the AGM of the Company in accordance with the Articles of Association.

Ms. Zhang is entitled to director's emolument of HK\$240,000 per annum.

Relationships

Apart from being the Company's executive Director and saved as disclosed above, Ms. Zhang does not have any relationships with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company or their respective associates as at the Latest Practicable Date.

Interests in Shares

As at the Latest Practicable Date, Ms. Zhang did not have any interest in Shares under Part XV of the SFO.

Information that needs to be disclosed and matters that need to be brought to the attention of the Shareholders

There is no information which is discloseable nor is/was Ms. Zhang involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters concerning Ms. Zhang that need to be brought to the attention of the Shareholders.

AGM AND PROXY ARRANGEMENT

The supplemental notice of the AGM is set out on pages 8 to 9 of this supplemental circular.

Pursuant to Rule 17.47(4) of the GEM Listing Rules and the Articles of Association, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides in good faith to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. An announcement on the poll results will be published by the Company after the AGM in the manner prescribed under the GEM Listing Rules.

A revised form of proxy for use at the AGM is enclosed with this supplemental circular and such revised form of proxy is also published on the Stock Exchange websites (www.hkexnews.hk) and the Company (www.huakangbiomedical.com). To be valid, the revised

LETTER FROM THE BOARD

form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a certified copy of that power of attorney or authority at the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the AGM (i.e. not later than 4:00 p.m. on Wednesday, 25 June 2025 (Hong Kong time)) or the adjourned meeting (as the case may be). Completion and delivery of the revised form of proxy will not preclude you from attending and voting at the AGM if you so wish, in such event, the authority of your proxy will be revoked.

The revised form of proxy is intended to be used for the resolutions specified in the notice of AGM and the AGM supplemental notice.

Shareholders who have not yet lodged the form of proxy which was published by the Company on 30 May 2025 (the "Original Form of Proxy") with the Company's branch share registrar and transfer office in Hong Kong

Any Shareholder who has not yet lodged the Original Form of Proxy with the Company's branch share registrar and transfer office in Hong Kong is requested to lodge only the revised form of proxy if he/she intends to appoint a proxy to attend the AGM on his/her behalf.

Shareholders who have already lodged the Original Form of Proxy with the Company's branch share registrar and transfer office in Hong Kong

Any Shareholder who has already lodged the Original Form of Proxy with the Company's branch share registrar and transfer office in Hong Kong should note that:

- (1) if no revised form of proxy is lodged by the Shareholder, the Original Form of Proxy will be treated as a valid form of proxy lodged by the Shareholder if duly completed. The proxy appointed under Original Form of Proxy will also be entitled to vote in accordance with the instructions previously given by the Shareholder or at his/her discretion (if no such instructions are given) on any resolution properly put to the AGM, including the new resolutions as set out in this supplemental circular and the AGM supplemental notice.
- (2) if the revised form of proxy is lodged by the Shareholder at or before 4:00 p.m. on Wednesday, 25 June 2025, the revised form of proxy will be treated as a valid form of proxy lodged by the Shareholder if duly completed.
- (3) if the revised form of proxy is lodged by the Shareholder after the closing time set out in the AGM supplemental notice, the revised form of proxy will be deemed invalid. It will not revoke the Original Form of Proxy previously lodged by the Shareholder. The Original Form of Proxy will be treated as a valid form of proxy if duly completed. The proxy appointed under the Original Form of Proxy will also be entitled to vote in accordance with the instructions previously given by the Shareholder or at his/her

LETTER FROM THE BOARD

discretion (if no such instructions are given) on any resolution properly put to the AGM (including the new resolutions as set out in this supplemental circular and the AGM supplemental notice).

CLOSURE OF REGISTER OF MEMBERS

For determining the entitlement to attend and vote at the meeting, the Register of Members of the Company will be closed from Tuesday, 24 June 2025 to Friday, 27 June 2025, both dates inclusive, during which period no transfer of Shares will be registered. In order to be eligible to attend and vote at the AGM, unregistered holders of Shares shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Monday, 23 June 2025.

RESPONSIBILITY STATEMENT

This supplemental circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this supplemental circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this supplemental circular misleading.

RECOMMENDATION

The Directors consider that the proposed re-election of Ms. Zhang is in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolution to be proposed at the AGM.

Yours faithfully,
For and on behalf of the Board
Huakang Biomedical Holdings Company Limited
ZHANG Shuguang
Chairman and Executive Director

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8622)

Reference is made to the notice of annual general meeting of **Huakang Biomedical Holdings Company Limited** (the “**Company**”) dated 30 May 2025 (the “**AGM Notice**”) which sets out the resolutions to be considered by shareholders of the Company (the “**Shareholder(s)**”) at the annual general meeting of the Company to be held at 1/F, Connaught Harbourfront House, No. 35–36 Connaught Road West, Sheung Wan, Hong Kong on Friday, 27 June 2025 at 4:00 p.m. (the “**AGM**”).

SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT due to the matters as set out in the supplemental circular of the Company dated 9 June 2025 (the “**Supplemental Circular**”), the resolutions under item numbered 2 stated in the AGM Notice should be deleted in its entirety and replaced by the following new resolutions under item numbered 2:

2. To re-elect, each as a separate resolution, the following directors:
 - (a) Mr. Zhang Shuguang as an executive director of the Company;
 - (b) Mr. Zhang Chunguang as an executive director of the Company;
 - (c) Dr. Bu Su as a non-executive director of the Company;
 - (d) Dr. Xu Ming as a non-executive director of the Company;
 - (e) Mr. Tsui Wing Tak as an independent non-executive director of the Company;
and
 - (f) Ms. Zhang Yujing as an executive director of the Company.

By Order of the Board
Huakang Biomedical Holdings Company Limited
ZHANG Shuguang
Chairman and Executive Director

Hong Kong, 9 June 2025

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

As at the date of this supplemental notice, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Ms. Zhang Yujing; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Tsui Wing Tak.

Notes:

1. All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”). The results of the poll will be published on the websites of GEM and the Company in accordance with the GEM Listing Rules.
2. Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of him. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant revised form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.
3. Where there are joint holders of any share of the Company, any one of such joint holders may vote at the AGM, either in person or by proxy, in respect of such share as if he were solely entitled thereto, but if more than one of such joint holders be present at the AGM, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose, seniority shall be determined by the order in which the names stand in the register of members in respect of the joint holding.
4. In order to be valid, the revised form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time appointed for the meeting (i.e. not later than 4:00 p.m. on Wednesday, 25 June 2025 (Hong Kong time)) or the adjourned meeting (as the case may be). Completion and return of the revised form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
5. For determining the entitlement to attend and vote at the meeting, the Register of Members of the Company will be closed from Tuesday, 24 June 2025 to Friday, 27 June 2025, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the AGM, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Monday, 23 June 2025.
6. If a black rainstorm warning or a tropical cyclone warning signal number 8 or above is hoisted at or after 8:00 a.m. on 27 June 2025, the AGM will not be held on 27 June 2025 but will be postponed to a later date and if postponed, the Company will as soon as practicable post an announcement on the Stock Exchange websites (www.hkexnews.hk) and the Company (www.huakangbiomedical.com).
7. Members of the Company or their proxies shall produce documents of their proof of identity when attending the AGM.
8. References to time and dates in this supplemental notice are to Hong Kong time and dates.